Vaxcyte, Inc.
HealthcareNASDAQ:PCVX · NASDAQ Global Select
+$0.17 today
Vol 1.02M · Avg 1.42M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-28.5%
avg -13.0%
ROIC
-32.5%
avg -41.6%
ROA
-25.2%
avg -33.8%
Analysis
ROA is currently the strongest return metric at -25.2% versus its period average of -33.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Grant E. Pickering | Co-Founder, Chief Executive Officer & Director | $1.44M | — | 58 | $496,939.00 | 0.34% |
Andrew L. Guggenhime | President & Chief Financial Officer | $960,230.00 | — | 58 | $104,395.00 | 0.07% |
Mikhail Eydelman | Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary | $752,712.00 | — | 44 | $41,732.00 | 0.03% |
Harp Dhaliwal | Chief Technical Operations Officer | $743,618.00 | — | 53 | $75,976.00 | 0.05% |
James Wassil | Executive Vice President & Chief Operating Officer | $614,730.00 | — | 57 | $160,744.00 | 0.11% |
Whitney Jones | Chief People Officer | — | — | — | — | — |
Chris Griffith | Chief Business & Strategy Officer | — | — | — | — | — |
Elvia Cowan | Senior VP of Finance & Chief Accounting Officer | — | — | 53 | $31,975.00 | 0.02% |
Janet Graesser | Senior Vice President of Corporate Affairs | — | — | — | — | — |
Jeff Fairman | Co-Founder & Vice President of Research | — | — | 62 | $15,000.00 | 0.01% |
Jeff Macdonald | Executive Director of Investor Relations | — | — | — | $15,000.00 | 0.01% |
Mike Mullette | Chief Commercial Officer | — | — | — | — | — |
Sam Iki | Senior Vice President of Project Management | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
12
$2.14M
Net Sentiment
$2.14M
Net selling
Most Active
Cowan Elvia
6 transactions
1–10 of 12
Analysis
Insiders reported 0 buys worth $0.00 and 12 sells worth $2.14M over the last 12 months. That adds up to net selling of $2.14M. Cowan Elvia was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$10.50B
Krystal Biotech, Inc.
NASDAQ:KRYS
$9.37B
TG Therapeutics, Inc.
NASDAQ:TGTX
$7.58B
Metsera, Inc.
MTSR
$7.43B
Alkermes plc
NASDAQ:ALKS
$7.38B
Arcellx, Inc.
ACLX
$6.73B
PTC Therapeutics, Inc.
NASDAQ:PTCT
$6.23B
CRISPR Therapeutics AG
NASDAQ:CRSP
$4.80B
Akero Therapeutics, Inc.
AKRO
$4.50B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.63B
Who manages PCVX?
Vaxcyte, Inc. (PCVX) lists 13 active executives. The top listed executive is Whitney Jones, Chief People Officer.
Are PCVX insiders buying or selling?
Recent insider activity shows net buying of $46.82M.
Explore More
Continue the stock analysis
Jump to another research area for this company.